Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

MRI of the hand and fingers
Malone, Jonathan C., Preston, Kevin S., Wessell, Daniel E. , Peterson, Jeffrey J., Garner, Hillary W. , Bestic, Joseph M.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 9-21

10.37549/ar2251 Get It

The incidence of lumbar spine surgery following Minimally Invasive Lumbar Decompression and Superion Indirect Decompression System for treatment of lumbar spinal stenosis: a retrospective review
Hagedorn, Jonathan M. , Yadav, Abhishek , D’Souza, Ryan S. , DeTemple, Nathan, Wolff, Jason S., Parmele, James B., Hagedorn, Jonathan M , D'Souza, Ryan S , Deer, Timothy R.

Mayo Clinic

Pain Practice | April 4, 2022 | Volume: 22 | Issue: 5 | Pages: 516-521

10.1111/papr.13111 | PMID 35373492 Get It

Abstract Introduction Lumbar spinal stenosis affects more than 200,000 adults in the United States, resulting in approximately 38,000 operations among the Medicare population and greater than $1.5 billion in hospital bills alone. Fortunately, Minimally Invasive Lumbar Decompression (MILD) and the Superion Indirect Decompression System have shown lasting benefit and cost savings compared to more aggressive surgical options. Objective Our primary objective was to retrospectively determine the rate of lumbar decompression surgery following the MILD and Superion procedures. Materials and Methods This was a pooled retrospective review of LSS patients who received MILD and/or Superion procedures between January 2011 and July 2019. Adult patients with CPT codes for MILD and Superion procedures were identified. Patients were included if they had a follow‐up visit at least 2 years from the procedure date, preprocedural MRI results, and surgical notes. Results A total of 199 patients were included in the final analysis, of which 57 patients (28.6%) underwent MILD procedure only, 124 patients (62.3%) underwent Superion only, and 18 patients (9.0%) underwent an MILD procedure initially followed by a Superion procedure. Two patients had an MILD procedure performed twice at the same level at separate encounters. A total of four patients in the entire cohort (2.0%; MILD 5.3%, Superion 0.8%) underwent subsequent lumbar spine surgery when followed for at least 2 years. It is notable that some of these patients may not have been surgical candidates and this may have skewed the results. Conclusions Patients undergoing minimally invasive decompression treatment of lumbar spinal stenosis have low rates of subsequent open surgery which potentially results in cost savings and a reduction in severe adverse events. The reason for low surgical rate may reflect improvement in their symptoms, a preference to avoid surgery, or being deemed not a surgical candidate.
PC2. THREE-DIMENSIONAL TISSUE RENDERING AND VOLUME ANALYSIS OF A NOVEL MEDIAL THIGH FLAP USING CT ANGIOGRAPHY: THE CHIMERIC GRACILIS AND PAP FLAP
Teven, Chad M. , Jokerst, Clint , Shrout, Max A., Laitinen, Marko A., Kruger, Erwin A., Casey, William J., Rebecca, Alanna M. , Hammond, Jacob B. , Kandi, Lyndsay A. , Flug, Jonathan A.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 35-35

10.1097/01.gox.0000828260.56790.38 Get It

Biomarker clustering in autosomal dominant Alzheimer's disease
Luckett, Patrick H. , Chen, Charlie, Gordon, Brian A. , Wisch, Julie K. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Wang, Qing , Marcus, Daniel C. , Koudelis, Deborah, Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Wisch, Julie K , Berman, Sarah , Noble, James M , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Marcus, Daniel, Joseph‐Mathurin, Nelly , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | April 1, 2022 | Volume: 19 | Issue: 1 | Pages: 274-284

10.1002/alz.12661 | PMID 35362200 Get It

AbstractINTRODUCTIONAs the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others.METHODSWe used hierarchical clustering to group 19 cross‐sectional biomarkers in autosomal dominant AD. Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO). Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.RESULTSThree primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers. Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO. Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.DISCUSSIONThese results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain
D’Souza, Ryan S. , Her, Yeng F , Schappell, Justin , Eller, Jennifer , Evans, Timothy C., Hagedorn, Jonathan M. , Langford, Brendan , Wilson, Rachel E, Eller, Jennifer S, Hagedorn, Jonathan M , D'Souza, Ryan S , Wilson, Rachel E.

Mayo Clinic

Expert Opinion on Pharmacotherapy | March 31, 2022 | Volume: 23 | Issue: 7 | Pages: 775-789

10.1080/14656566.2022.2060741 | PMID 35354341 Get It

How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
Bloch, Evan M. , Tobian, Aaron A.R. , Gniadek, Thomas J. , Cachay, Edward R. , Kafka, Kimberly, Marshall, Christi E., Heath, Sonya L. , Forthal, Donald N. , Fukuta, Yuriko , Huamán, Moisés A. , Ziman, Alyssa , Adamski, Jill , Gerber, Jonathan M. , Cruser, Daniel, Patel, Bela , Metcalf, Ryan A. , Reisler, Ronald B. , Yarava, Anusha , Lane, Karen , McBee, Nichol , Gawad, Amy L., Abinante, Matthew, Broderick, Patrick , Sullivan, David , Ziman, Alyssa , Adamksi, Jill , Raval, Jay S , Metcalf, Ryan A , Tobian, Aaron A R , Huaman, Moises A , Sullivan, David J , Shoham, Shmuel , Hanley, Daniel F. , Meisenberg, Barry R. , Shenoy, Aarthi , Paxton, James H , Levine, Adam C , Kassaye, Seble , Mosnaim, Giselle S , Anjan, Shweta , Raval, Jay S. , Zand, Martin S. , Broderick, Patrick B., Casadevall, Arturo , Gebo, Kelly A

Mayo Clinic

Transfusion | March 30, 2022 | Volume: 62 | Issue: 5 | Pages: 933-941

10.1111/trf.16871 | PMID 35352362 Get It

AbstractConvalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID‐19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID‐19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID‐19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.
COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates
Levy, Emily R. , Dearani, Joseph A. , Blumenthal, Jennifer , Johnson, Jonathan N. , Overman, David M. , Stephens, Elizabeth H. , Dearani, Joseph A. , Levy, Emily R , Chiotos, Kathleen

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 28, 2022 | Volume: 13 | Issue: 3 | Pages: 287-292

10.1177/21501351221085966 | PMID 35341384 Get It

Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit
Mishra, Sanskriti , Shekunov, Julia , Derscheid, Della J. , Canterbury, Elizabeth, Leung, Jonathan G. , Canterbury, Elizabeth A, Leung, Jonathan G

Mayo Clinic

Case Reports in Psychiatry | March 25, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-6

10.1155/2022/2149301 | PMID 35371580 Get It

Guanfacine is a selective alpha-2a adrenoreceptor agonist that with overdose can cause symptoms ranging from mild sedation to coma, respiratory depression, hyporeflexia, hypotonia, bradycardia, and hypotension. Despite a well-defined and predictable toxidrome, variations can be seen based on multiple factors including age, quantity ingested, organ functions, coingestions, time since ingestion, and specific dosage form. Here, we describe two cases of delayed presentation of extended release guanfacine toxicity and highlight the variations encountered in the toxidrome presentation. These cases bring to attention the importance of maintaining a high suspicion for such atypical presentations, keeping in mind the limitations of managing these complications on an inpatient psychiatric unit.
Kaizen Process Improvement in Radiology: Primer for Creating a Culture of Continuous Quality Improvement
Flug, Jonathan A. , Stellmaker, Jessica A. , Sharpe, Richard E. , Jokerst, Clinton, Tollefson, Chris , Bowman, Andrew W. , Nordland, Michelle, Hannafin, Cathy L , Froemming, Adam T. , Jokerst, Clinton E , Tollefson, Chris D , Bowman, Andrew W , Flug, Jonathan A , Nordland, Michelle R.

Mayo Clinic

RadioGraphics | March 25, 2022 | Volume: 42 | Issue: 3 | Pages: 919-928

10.1148/rg.210086 | PMID 35333633 Get It

Differences in postoperative quality of life in young, early elderly, and late elderly patients undergoing surgical treatment for degenerative cervical myelopathy
Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F., Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F.

Mayo Clinic

Journal of Neurosurgery: Spine | March 25, 2022 | Volume: 37 | Issue: 3 | Pages: 339-349

10.3171/2022.1.spine211157 | PMID 35276658 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) is a common progressive spine disorder affecting predominantly middle-aged and elderly populations. With increasing life expectancy, the incidence of CSM is expected to rise further. The outcomes of elderly patients undergoing CSM surgery and especially their quality of life (QOL) postoperatively remain undetermined. This study retrospectively reviewed patients to identify baseline differences and validated postoperative patient-reported outcome (PRO) measures in elderly patients undergoing CSM surgery. METHODS The multi-institutional, neurosurgery-specific NeuroPoint Quality Outcomes Database was queried to identify CSM patients treated surgically at the 14 highest-volume sites from January 2016 to December 2018. Patients were divided into three groups: young (< 65 years), early elderly (65–74 years), and late elderly (≥ 75 years). Demographic and PRO measures (Neck Disability Index [NDI] score, modified Japanese Orthopaedic Association [mJOA] score, EQ-5D score, EQ-5D visual analog scale [VAS] score, arm pain VAS, and neck pain VAS) were compared among the groups at baseline and 3 and 12 months postoperatively. RESULTS A total of 1151 patients were identified: 691 patients (60%) in the young, 331 patients (28.7%) in the early elderly, and 129 patients (11.2%) in the late elderly groups. At baseline, younger patients presented with worse NDI scores (p < 0.001) and lower EQ-5D VAS (p = 0.004) and EQ-5D (p < 0.001) scores compared with early and late elderly patients. No differences among age groups were found in the mJOA score. An improvement of all QOL scores was noted in all age groups. On unadjusted analysis at 3 months, younger patients had greater improvement in arm pain VAS, NDI, and EQ-5D VAS compared with early and late elderly patients. At 12 months, the same changes were seen, but on adjusted analysis, there were no differences in PROs between the age groups. CONCLUSIONS The authors’ results indicate that elderly patients undergoing CSM surgery achieved QOL outcomes that were equivalent to those of younger patients at the 12-month follow-up.